news 
A New Hope in TBI Treatment: Foralumab Shows Early Promise Against Traumatic Brain Injuries
In a breakthrough that could potentially revolutionize the treatment of traumatic brain injuries (TBI), a novel nasal spray has demonstrated early promise in reducing inflammation and promoting healing. This innovative approach may offer a safer, more effective alternative to traditional therapies for patients suffering from TBI.
Developed by researchers at a leading pharmaceutical company, foralumab is an antibody that targets the CD80 receptor on immune cells. In a recent study published in a prestigious scientific journal, investigators found that administering this medication via nasal spray significantly reduced inflammation and improved cognitive function in animal models of TBI.
This study marks only the first step in proving that a new drug or vaccine can work as hoped. Quite obviously, more research is needed to validate the drug’s potential for TBI treatment. But foralumab has already shown early positive results in human trials for multiple sclerosis (MS), with other trials for Alzheimer’s and amyotrophic lateral sclerosis (ALS) having started or soon to be underway.
That raises hope that this antibody can become a new and much-needed treatment option for numerous brain conditions, including TBI.
Source: https://gizmodo.com/a-nasal-spray-for-concussions-shows-early-promise-2000570121
